1. Albumin–globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
- Author
-
Nakanishi, Yu, Masuda, Takeshi, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Mimae, Takahiro, Nakashima, Taku, Miyamoto, Shintaro, Tsutani, Yasuhiro, Iwamoto, Hiroshi, Fujitaka, Kazunori, Miyata, Yoshihiro, Hamada, Hironobu, Okada, Morihito, and Hattori, Noboru
- Subjects
- *
NON-small-cell lung carcinoma , *RECEIVER operating characteristic curves , *CELL receptors , *LOGISTIC regression analysis , *DEATH receptors - Abstract
Background: Anti-programmed cell death receptor (PD)-1 antibody treatment results in better prognosis than standard chemotherapy in patients with non-small cell lung cancer (NSCLC), especially those with high PD-ligand 1 (PD-L1) expression. However, several studies have reported a lack of antitumor effect of PD-1 antibody, even in patients with high PD-L1 expression. Therefore, reliable predictors of treatment response are urgently needed. The albumin–globulin ratio (AGR) is associated with prognosis in several cancers. We aimed to determine whether AGR is a predictive biomarker of anti-PD-1 antibody response in patients with NSCLC. Patients and methods: Seventy-four NSCLC patients treated with anti-PD-1 antibody were retrospectively enrolled. Patients with driver mutations were excluded. Results: The mean AGR was significantly higher in the disease control (DC) group than in the progressive disease (PD) group (p < 0.001). Receiver operating characteristic curve analysis revealed an AGR cutoff value for dividing patients into the DC or PD groups of 1.17. Multivariate logistic regression analysis showed that a high AGR (≥1.17, cutoff value) was an independent predictor of DC (p = 0.001). Progression-free survival (PFS) and overall survival (OS) were significantly longer in the high-AGR group than in the low-AGR group (p = 0.008, p = 0.002, respectively). Multivariate Cox regression analysis of PFS and OS showed that high AGR was an independent prognostic factor (p = 0.020, p < 0.001, respectively). Conclusion: Pretreatment serum AGR may be a useful predictor for DC and prognostic factor of anti-PD-1 antibody in patients with NSCLC. The clinical utility of AGR still needs to be confirmed in a prospective analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF